Resistance in Vulvovaginal Candidiasis (VVC)—A Growing Problem

Key Facts About Drug Resistance in VVC

The prevalence of VVC caused by non-albicans Candida has increased tremendously—and these species are less susceptible to fluconazole¹
Although Candida albicans is still the most common cause, non-albicans species now account for 30% of vaginal yeast infections. Many are resistant to commonly prescribed antifungal agents, making treatment more challenging.¹

Fluconazole resistance often begins in the gut
Oral fluconazole is systemic, and a significant amount of the drug remains in the GI tract. Repeated use reduces the C. albicans population in the gut, allowing resistant non-albicans species to thrive and reach the vagina.²

Fluconazole doses have increased dramatically
The number of fluconazole pills prescribed has more than doubled since 2005, and nearly 60% of patients get more than 1 fluconazole tablet initially.³ These dosing trends may be another indicator of growing resistance.

Optimal treatment for non-albicans VVC is not yet established; CDC Guidelines suggest a non-fluconazole azole for 7-14 days first-line⁴
The Guidelines also include recommendations for treating VVC in certain populations, including women who are pregnant, diabetic, or immunocompromised.